TY - JOUR
T1 - Establishing the Link between Lean Mass and Grip Strength Cut Points with Mobility Disability and Other Health Outcomes
T2 - Proceedings of the Sarcopenia Definition and Outcomes Consortium Conference
AU - Cawthon, Peggy M.
AU - Travison, Thomas G.
AU - Manini, Todd M.
AU - Patel, Sheena
AU - Pencina, Karol M.
AU - Fielding, Roger A.
AU - Magaziner, Jay M.
AU - Newman, Anne B.
AU - Brown, Todd
AU - Kiel, Douglas P.
AU - Cummings, Steve R.
AU - Shardell, Michelle
AU - Guralnik, Jack M.
AU - Woodhouse, Linda J.
AU - Pahor, Marco
AU - Binder, Ellen
AU - D'Agostino, Ralph B.
AU - Quian-Li, Xue
AU - Orwoll, Eric
AU - Landi, Francesco
AU - Orwig, Denise
AU - Schaap, Laura
AU - Latham, Nancy K.
AU - Hirani, Vasant
AU - Kwok, Timothy
AU - Pereira, Suzette L.
AU - Rooks, Daniel
AU - Kashiwa, Makoto
AU - Torres-Gonzalez, Moises
AU - Menetski, Joseph P.
AU - Correa-De-Araujo, Rosaly
AU - Bhasin, Shalender
N1 - Funding Information:
This research and the Sarcopenia Definitions and Outcomes Conference was supported by a cooperative agreement from the National Institute on Aging (1UO1AG051421) and by the Foundation for National Institutes of Health. We thank Dr. Lyndon Joseph of the National Institute on Aging, the project’s Program Officer for his guidance and oversight of the project. Dr. Rosaly Correa-De-Arauajo is an employee of the National Institute on Aging. Her participation or the materials should not be interpreted as representing the official viewpoint of the U.S. Department of Health and Human Services, the National Institutes of Health or the National Institute on Aging, except where noted. We thank Kevin Wilson and Tom Kelly of Hologic Corporation for their assistance in harmonizing the Dual-Energy X-Ray Absorptiometry (DXA) data. Funding support for the individual studies that comprise the pooled data set is gratefully acknowledged. MrOS (US): The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health funding. The following institutes provide support: the National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Center for Advancing Translational Sciences (NCATS), and National Institute of Health (NIH) Roadmap for Medical Research under the following grant numbers: U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128. MrOS Hong Kong: MrOS in Hong Kong was supported by a U.S. National Institute of Health R01 Grant AR049439-01A1, the Research Grants Council Earmarked Grant CUHK 4101/02M, and a direct grant for research of The Chinese University of Hong Kong (No. 2041657). MrOS Sweden: Financial support was received from the Swedish Research Council (2006-3832), the Swedish Foundation for Strategic Research, the Swedish Research Council grant for the Gothenburg Region of Sweden (ALF/FUA) research grant in Gothenburg, the Lundberg Foundation, the Torsten and Ragnar Söderberg’s Foundation, Petrus and Augusta Hedlunds Foundation, the Västra Götaland Foundation, the Göteborg Medical Society and the Novo Nordisk Foundation. SOF: The Study of Osteoporotic Fractures (SOF) is supported by National Institutes of Health funding. The National Institute on Aging (NIA) provides support under the following grant numbers: R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, and R01 AG027576. Health Aging and Body Composition Study (Health ABC): This study was funded by the National Institutes of Aging. This research was supported by NIA contracts N01AG62101, N01AG62103, and N01AG62106. Cardiovascular Health Study (CHS): This CHS research was supported by National Institute of Heart, Lung and Blood Institute (NHLBI) contracts N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086; N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, N01-HC-85239, and by HHSN268201200036C and NHLBI grants HL080295, HL087652, HL105756, HL103612 with additional contribution from National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through AG-023629, AG-15928, AG-20098, and AG-027058 from the NIA. Framingham Osteoporosis Study (FOS)/Framingham Heart Study (FHS): The study was funded by grants from the US National Institute for Arthritis, Musculoskeletal and Skin Diseases and National Institute on Aging (R01 AR 41398 and U24AG051129; DPK and R01AR057118. The Framingham Heart Study of the National Heart, Lung, and Blood Institute of the National Institutes of Health and Boston University School of Medicine were supported by the National Heart, Lung, and Blood Institute’s Framingham Heart Study (N01-HC-25195). Johnson County Study: The Johnston County Osteoarthritis Project is supported in part by cooperative agreements S043, S1734, and S3486 from the Centers for Disease Control and Prevention/Association of Schools of Public Health; the NIAMS Multipurpose Arthritis and Musculoskeletal Disease Center grant 5-P60-AR30701; and the NIAMS Multidisciplinary Clinical Research Center grant 5 P60 AR49465-03. Concord Health and Ageing in Men Project: CHAMP is funded by the National Health and Medical Research Council (project grant number 301916) and the Ageing and Alzheimer’s Institute. LASA: The Longitudinal Aging Study Amsterdam (LASA) is largely supported by a grant from the Netherlands Ministry of Health, Welfare and Sports, Directorate of Long-Term Care. The data collection in 2012–2013 was financially supported by the Netherlands Organization for Scientific Research (NWO) in the framework of the project “New Cohorts of young old in the 21st century” (File Number 480-10-014).
Publisher Copyright:
© 2019 The Author(s) 2019. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
PY - 2020/7
Y1 - 2020/7
N2 - Background: Lack of consensus on how to diagnose sarcopenia has limited the ability to diagnose this condition and hindered drug development. The Sarcopenia Definitions and Outcomes Consortium (SDOC) was formed to develop evidence-based diagnostic cut points for lean mass and/or muscle strength that identify people at increased risk of mobility disability. We describe here the proceedings of a meeting of SDOC and other experts to discuss strategic considerations in the development of evidence-based sarcopenia definition. Methods: Presentations and panel discussions reviewed the usefulness of sarcopenia as a biomarker, the analytical approach used by SDOC to establish cut points, and preliminary findings, and provided strategic direction to develop an evidence-based definition of sarcopenia. Results: The SDOC assembled data from eight epidemiological cohorts consisting of 18,831 participants, clinical populations from 10 randomized trials and observational studies, and 2 nationally representative cohorts. In preliminary assessments, grip strength or grip strength divided by body mass index was identified as discriminators of risk for mobility disability (walking speed <0.8 m/s), whereas dual-energy X-ray absorptiometry-derived lean mass measures were not good discriminators of mobility disability. Candidate definitions based on grip strength variables were associated with increased risk of mortality, falls, mobility disability, and instrumental activities of daily living disability. The prevalence of low grip strength increased with age. The attendees recommended the establishment of an International Expert Panel to review a series of position statements on sarcopenia definition that are informed by the findings of the SDOC analyses and synthesis of literature. Conclusions: International consensus on an evidence-based definition of sarcopenia is needed. Grip strength - absolute or adjusted for body mass index - is an important discriminator of mobility disability and other endpoints. Additional research is needed to develop a predictive risk model that takes into account sarcopenia components as well as age, sex, race, and comorbidities.
AB - Background: Lack of consensus on how to diagnose sarcopenia has limited the ability to diagnose this condition and hindered drug development. The Sarcopenia Definitions and Outcomes Consortium (SDOC) was formed to develop evidence-based diagnostic cut points for lean mass and/or muscle strength that identify people at increased risk of mobility disability. We describe here the proceedings of a meeting of SDOC and other experts to discuss strategic considerations in the development of evidence-based sarcopenia definition. Methods: Presentations and panel discussions reviewed the usefulness of sarcopenia as a biomarker, the analytical approach used by SDOC to establish cut points, and preliminary findings, and provided strategic direction to develop an evidence-based definition of sarcopenia. Results: The SDOC assembled data from eight epidemiological cohorts consisting of 18,831 participants, clinical populations from 10 randomized trials and observational studies, and 2 nationally representative cohorts. In preliminary assessments, grip strength or grip strength divided by body mass index was identified as discriminators of risk for mobility disability (walking speed <0.8 m/s), whereas dual-energy X-ray absorptiometry-derived lean mass measures were not good discriminators of mobility disability. Candidate definitions based on grip strength variables were associated with increased risk of mortality, falls, mobility disability, and instrumental activities of daily living disability. The prevalence of low grip strength increased with age. The attendees recommended the establishment of an International Expert Panel to review a series of position statements on sarcopenia definition that are informed by the findings of the SDOC analyses and synthesis of literature. Conclusions: International consensus on an evidence-based definition of sarcopenia is needed. Grip strength - absolute or adjusted for body mass index - is an important discriminator of mobility disability and other endpoints. Additional research is needed to develop a predictive risk model that takes into account sarcopenia components as well as age, sex, race, and comorbidities.
KW - Grip strength cut-points
KW - Lean mass cut-points
KW - Mobility disability
KW - Risk factors for mobility disability
KW - Sarcopenia
UR - http://www.scopus.com/inward/record.url?scp=85086749843&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086749843&partnerID=8YFLogxK
U2 - 10.1093/gerona/glz081
DO - 10.1093/gerona/glz081
M3 - Article
C2 - 30869772
AN - SCOPUS:85086749843
SN - 1079-5006
VL - 75
SP - 1317
EP - 1323
JO - Journals of Gerontology - Series A Biological Sciences and Medical Sciences
JF - Journals of Gerontology - Series A Biological Sciences and Medical Sciences
IS - 7
ER -